The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,104,050 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis. The funding supports research to investigate the mechanisms by which the Plasmodium falciparum parasite impairs neutrophil function, thereby increasing susceptibility to invasive bacterial infections in malaria patients. Key objectives include identifying the molecular pathways by...
This federal Project Grant award of $791,864, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify the molecular factors that control chromatin organization and gene regulation in the human malaria parasite Plasmodium falciparum. The key objectives of the project are to elucidate the importance of long non-coding RNAs (lncRNAs) in parasite development, virulence, and...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $375,000.00 to the University of South Florida to conduct research on the functions of messenger ribonucleoproteins (mRNPs) in regulating RNA metabolism in the malaria parasite Plasmodium falciparum. The key objectives of this 5-year project are to: 1) identify molecular markers and characterize the protein and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $700,288 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of South Florida. The grant, titled "Phenotype-Based Screens to Identify Genetic Factors Associated with Gametocyte Development in Plasmodium falciparum," runs from November 2024 to October 2029. The project aims to use a functional genomics approach to identify P. falciparum genes essential for the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $459,131 to The Ohio State University to conduct research focused on the essential functions of the mitochondrion in malaria parasites. The goal is to expand the druggable parasite proteome and identify new therapeutic targets within the parasite mitochondrion, which is a promising source of drug targets due to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $587,318 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Oregon Health & Science University (OHSU). The funding supports the optimization of a next-generation antimalarial drug candidate, ELQ-596, to enable once-monthly oral prophylaxis in humans. Specifically, the research aims to enhance the structural features of ELQ-596 to improve its intrinsic anti-plasmodial activity,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $813,160 Project Grant under CFDA 93.855 Allergy and Infectious Diseases Research to develop mRNA-LNP combination vaccines targeting multiple life cycle stages and species of the human malaria parasite. The primary focus is on vaccines targeting the pre-erythrocytic (PEV) and transmission-blocking (TBV) stages of Plasmodium falciparum and Plasmodium vivax malaria. Key components include evaluating the protective efficacy...
The University of Georgia Research Foundation was awarded a $540,193 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The 12-month award, effective August 22, 2023, supports research to investigate the role of calcium-binding proteins and other secretory pathway components in the exocytosis of organelles critical for the invasion and egress of the malaria parasite Plasmodium falciparum...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $310,492 to the University of Washington to study Plasmodium-specific immune evasion mechanisms. The research aims to characterize the circumsporozoite protein (CSP)-specific memory B cell pool generated during Plasmodium infection versus vaccination, and identify the impact of prior infection on the response to...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), funds research to investigate the role of TAM receptors in modulating the humoral immune response against parasitic infections, particularly malaria. The $520,809 award, effective from September 5, 2024 to August 31, 2029, will support a research program at Rosalind Franklin University of Medicine & Science...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,056 in funding to The Washington University to conduct research on heme homeostasis in the malaria parasite Plasmodium falciparum. The research aims to identify parasite proteins involved in maintaining heme levels and explore their potential as novel antimalarial drug targets. The award period runs from July 16, 2025 to January 15, 2027. The research will utilize both unbiased and directed approaches to characterize heme-binding proteins in the parasite and investigate their role in heme detoxification and homeostasis. Findings from this project may reveal new insights into the parasite's heme handling mechanisms and provide opportunities for developing innovative antimalarial therapeutics that disrupt heme homeostasis.